PHAT — Phathom Pharmaceuticals, Inc.

Summary of Phathom Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Full Year 2025 Revenue: $175.1 million, a 217% increase year-over-year.
• Q4 Revenue: $57.6 million, aligning with pre-released estimates and reflecting solid sequential growth.
• Cash Operating Expenses (Q4): $50.3 million, better than the guided target of less than $55 million.
• Net Cash Usage (Q4): Approximately $5 million, down 64% from Q3.
• Gross Margin: Approximately 87% for both Q4 and full year.
• Loss from Operations (Q4): Approximately $320,000, a 95% improvement compared to Q3.
• Cash Position: Ended 2025 with about $130 million in cash and cash equivalents.

2. Strategic Updates and Business Highlights

• Phathom has enhanced its capital structure by renegotiating term loan agreements, reducing interest obligations, and extending maturity dates to February 2029.
• The company successfully completed a $130 million equity offering to strengthen its balance sheet.
• The sales organization is nearly fully staffed with over 285 of 300 positions filled, following a national sales meeting that generated positive sentiment.
• VOQUEZNA has achieved over 1.1 million total prescriptions filled, with Q4 seeing 273,000 prescriptions, a 21% quarter-over-quarter growth in covered prescriptions.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $320 million and $345 million, with a gross margin of approximately 80%.
• Cash Operating Expenses for 2026: Anticipated to be between $235 million and $255 million, reflecting a 14% decrease compared to 2025.
• The company aims to achieve operational profitability by Q3 2026 and cash flow positivity by 2027.
• Revenue is expected to follow a similar pattern as 2025, with approximately 40% in the first half and 60% in the second half of the year.

4. Bad News, Challenges, or Points of Concern

• Seasonality Effects: Q1 is expected to be the weakest quarter due to typical seasonality and recent winter storms impacting sales.
• Competitive Pressures: The entry of new competitors in the P-CAB space could pose challenges, although management believes it may ultimately benefit category awareness.
• Prescription Trends: There are concerns about the accuracy of IQVIA prescription data, which may underreport actual performance.

5. Notable Q&A Insights

• Management emphasized the importance of growing writing frequency among gastroenterologists, with positive trends observed in prescription adoption.
• There is no immediate plan for broad Medicare coverage for VOQUEZNA, but incremental coverage is expected as familiarity with the drug increases.
• The sales force is projected to reach full productivity within a few months, with ongoing efforts to deepen relationships with gastroenterologists.
• Management remains focused on executing their current strategy without diversifying too quickly into new products or indications beyond VOQUEZNA and EoE.

Overall, Phathom Pharmaceuticals reported strong financial performance in 2025, with significant growth in revenue and improvements in cash management. The company is strategically positioned for continued growth in 2026, despite facing some seasonal headwinds and competitive pressures.